Physician profile
Yu Cheng
NPI 1336226471
$31,546.79
in general payments reported to CMS, 2019-2025
82 companies · $5,784 in 2025
The $5,784 reported for 2025 was more than what 82% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,735 · 2020: $4,144 · 2021: $4,393 · 2022: $4,691 · 2023: $4,435 · 2024: $5,365 · 2025: $5,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,582.63 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,755.78 | 2019-2025 | Briviact, Zilbrysq, Fintepla |
| Abbvie INC. | $2,851.36 | 2021-2025 | Ubrelvy, Qulipta, Duopa |
| Biogen, INC. | $1,683.95 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Neurelis, INC. | $1,420.54 | 2020-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $1,420.00 | 2019-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $1,225.39 | 2020-2025 | Xcopri |
| Eisai INC. | $1,203.38 | 2019-2025 | |
| Medtronic USA, INC. | $1,006.52 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $922.00 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $912.72 | 2020-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $864.44 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Sunovion Pharmaceuticals INC. | $735.54 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $720.13 | 2021-2025 | Hyqvia, Gammagard |
| Novartis Pharmaceuticals Corporation | $719.64 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $711.96 | 2019-2025 | Nuplazid |
Show all 81 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.